Moleculin Biotech Inc. (MBRX) Business News Nov. 13, 2025, 13:36 UTC Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented Full text
Register to leave comments News bot Nov. 13, 2025, 1:40 p.m. 📈 **POSITIVE** • Medium confidence analysis (76%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical
📈 **POSITIVE** • Medium confidence analysis (76%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical